Compare ATER & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATER | VTGN |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 10.8M |
| IPO Year | 2019 | 2014 |
| Metric | ATER | VTGN |
|---|---|---|
| Price | $0.64 | $0.26 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 2.9M | ★ 20.8M |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $68,975,000.00 | N/A |
| Revenue This Year | $8.90 | $33.96 |
| Revenue Next Year | $6.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.35 | $0.20 |
| 52 Week High | $1.87 | $5.14 |
| Indicator | ATER | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.37 | 49.90 |
| Support Level | $0.62 | $0.22 |
| Resistance Level | $0.73 | $0.32 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 39.76 | 13.69 |
Aterian Inc is a consumer products company that operates through online retail channels, including Amazon, Walmart, Target, as well as its own direct-to-consumer websites. The company develops and manages a portfolio of owned brands, which are either internally incubated or acquired, offering products across multiple categories such as home and kitchen appliances, kitchenware, air quality appliances, health and beauty products, and essential oils. Its primary brands include Squatty Potty, HomeLabs, Mueller Living, PurSteam, Healing Solutions, and Photo Paper Direct. The company generates revenue mainly through the online sale of its consumer products, with substantially all sales derived from the Amazon U.S. marketplace.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.